Pharming Group announces the publication of its 2020 Annual Report and convenes its 2021 AGM

Annual General Meeting of Shareholders: Annual General Meeting of Shareholders: In accordance with precautionary measures invoked by the Dutch government's emergency COVID-legislation due to the ongoing and extraordinary circumstances of the COVID-19 pandemic, and with the health and safety of shareholders and employees a priority, the Company will hold a fully virtual AGM. The meeting will be available to watch via a live webcast. Please refer to the Notice to Convene document on the...

The Netherlands, 06/04/2021 (informazione.news - comunicati stampa - scienza e tecnologia)

In accordance with precautionary measures invoked by the Dutch government's emergency COVID-legislation due to the ongoing and extraordinary circumstances of the COVID-19 pandemic, and with the health and safety of shareholders and employees a priority, the Company will hold a fully virtual AGM. The meeting will be available to watch via a live webcast. Please refer to the Notice to Convene document on the Company's website, www.pharming.com under Investors/Shareholders' Meetings for further details regarding registration, voting by proxy and asking questions during the meeting.

Pharming Group N.V. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.

The flagship of our portfolio is our recombinant human C1 esterase inhibitor (rhC1INH) franchise. C1INH is a naturally occurring protein that down regulates the complement cascade in order to control inflammation in affected tissues.

Our lead product, RUCONEST®, is the first and only plasma-free rhC1INH protein replacement therapy. It is approved for the treatment of acute hereditary angioedema (HAE) attacks. We are commercializing RUCONEST® in the United States , the European Union and the United Kingdom through our own sales and marketing organization, and the rest of the world through our distribution network.

In addition, we are investigating the clinical efficacy of rhC1INH in the treatment of further indications, including pre-eclampsia, acute kidney injury and severe pneumonia as a result of COVID-19 infections.

We are also studying our oral precision medicine, leniolisib (a phosphoinositide 3-kinase delta, or PI3K delta, inhibitor), for the treatment of activated PI3K delta syndrome, or APDS, in a registration enabling Phase 2/3 study in the United States and Europe .

Furthermore, we are leveraging our transgenic manufacturing technology to develop next-generation protein replacement therapies, most notably for Pompe disease, which is currently in preclinical development.

Sijmen de Vries, CEO: T: +31 71 524 7400
Susanne Embleton , Investor Relations Manager: T: +31 71 524 7400 E: s.embleton@pharming.com

Victoria Foster Mitchell / Alex Shaw / Mary Whittow
T: +44 203 727 1000

Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

Logo - https://mma.prnewswire.com/media/1454235/Pharming_Group_NV_Logo.jpg